---
layout: default
title: Baricitinib
parent: 僅模型預測 (L5)
nav_order: 47
evidence_level: L5
indication_count: 2
---

# Baricitinib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Baricitinib: From No Established Indication to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome

## One-Sentence Summary

Baricitinib is a JAK1/JAK2 inhibitor whose original indication data is not available in this evidence pack.
The TxGNN model predicts a possible association with **Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome**,
but this prediction is supported by **0 clinical trials** and **0 publications**, and no biological rationale connects the mechanism to this rare developmental disorder.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available (no approved indications recorded in evidence pack) |
| Predicted New Indication | Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Germany Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known general pharmacology, baricitinib is a JAK1/JAK2 inhibitor used to modulate inflammatory signaling pathways; however, this evidence pack contains no confirmed original indication, no MOA detail, and no safety data to anchor a mechanistic comparison.

Colobomatous microphthalmia-rhizomelic dysplasia syndrome is a rare congenital disorder typically linked to genetic mutations affecting eye and skeletal development (e.g., transcription factor or ciliary gene defects), not to inflammatory or autoimmune pathways. There is no known biological pathway connecting JAK1/JAK2 inhibition to this developmental syndrome.

Given the complete absence of clinical trial or literature support, and the structural/developmental (rather than inflammatory) nature of the predicted disease, this TxGNN score most likely reflects graph-embedding proximity rather than a genuine pharmacological signal, and should be treated as a likely false positive pending further validation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Germany Market Information

No marketing authorizations recorded — this drug is currently not marketed in Germany (0 licenses on file).

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There is no clinical, literature, or mechanistic evidence supporting this indication — only a TxGNN similarity score with no biological plausibility for a congenital developmental syndrome. Core drug-level data (MOA, indications, safety) are also missing, making any repurposing assessment premature.

**To proceed, the following is needed:**
- TFDA/BfArM package insert (warnings, contraindications) — currently blocking (DG001)
- Verified original mechanism of action (DrugBank API query) — currently high priority (DG002)
- Confirmed original approved indication(s) for baricitinib
- Independent literature or preclinical evidence linking JAK inhibition to this syndrome before any further evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

